Calliditas Announces Filing with UK MHRA for Kinpeygo in IgA Nephropathy
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics AB has announced that its partner STADA Arzneimittel AG has submitted a request to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to convert the conditional marketing authorization for Kinpeygo®, a treatment for primary IgA nephropathy (IgAN), to standard, or 'full', marketing authorization.
October 03, 2023 | 8:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas' partner STADA's request for full marketing authorization for Kinpeygo® in the UK could potentially boost Calliditas' revenues if approved.
The news of STADA's request for full marketing authorization for Kinpeygo® in the UK is directly relevant to Calliditas as it could potentially lead to increased sales and revenues for the company if the request is approved. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100